Regulation & law · 31/10/2023

US FDA Approves Zuranolone for Post-Partum Depression Treatment, DEA Schedules it as Schedule IV Controlled Substance

The US FDA approved ZURZUVAE (zuranolone) capsules for post-partum depression treatment on August 4, 2023, and the DEA has scheduled it as a Schedule IV controlled substance, making it available to the public.